Dolutegravir represents a significant advancement in HIV treatment. As an integrase strand transfer inhibitor (INSTI), it has revolutionized HIV therapy with its high efficacy, favorable safety profile, and high barrier to resistance.

Mechanism of Action:
Dolutegravir works by blocking the HIV integrase enzyme, which the virus needs to insert its genetic material into human DNA. By preventing this integration, Dolutegravir stops the virus from replicating and spreading throughout the body.

Clinical Efficacy:
Clinical trials have demonstrated that Dolutegravir-based regimens achieve viral suppression in over 85% of treatment-naive patients. The medication shows superior efficacy compared to many other antiretroviral drugs, with faster time to viral suppression.

Safety Profile:
Dolutegravir is generally well-tolerated with fewer side effects compared to older HIV medications. Common side effects are usually mild and may include headache, nausea, and insomnia. Serious side effects are rare.

High Barrier to Resistance:
One of Dolutegravir most important features is its high genetic barrier to resistance. The virus requires multiple mutations to develop resistance, making treatment failure less likely.

WHO Recommendations:
The World Health Organization recommends Dolutegravir as a preferred first-line and second-line treatment option for all populations, including pregnant women and children.

Dosing Convenience:
Dolutegravir is typically taken once daily, which improves adherence to treatment. The 50mg dose is standard for most patients, while a 10mg dispersible formulation is available for pediatric use.

Cost-Effectiveness:
Generic Dolutegravir has made HIV treatment more accessible and affordable, particularly in low and middle-income countries where the HIV burden is highest.